Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan + Cladribine + LDAC in Treated Secondary AML
NCT04848974Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of uproleselan in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2021; status: completed.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04848974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848974.